AlloVir (AlloVir) Debt-to-Equity : 0.19 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is AlloVir Debt-to-Equity?

AlloVir's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.78 Mil. AlloVir's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.65 Mil. AlloVir's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $145.78 Mil. AlloVir's debt to equity for the quarter that ended in Dec. 2023 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AlloVir's Debt-to-Equity or its related term are showing as below:

ALVR' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.23 Med: 0.13 Max: 0.19
Current: 0.19

During the past 6 years, the highest Debt-to-Equity Ratio of AlloVir was 0.19. The lowest was -0.23. And the median was 0.13.

ALVR's Debt-to-Equity is ranked worse than
54.65% of 1076 companies
in the Biotechnology industry
Industry Median: 0.15 vs ALVR: 0.19

AlloVir Debt-to-Equity Historical Data

The historical data trend for AlloVir's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Debt-to-Equity Chart

AlloVir Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.23

0.03

0.13

0.16

0.19

AlloVir Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.16	0.18	0.14	0.17	0.19

Competitive Comparison of AlloVir's Debt-to-Equity

For the Biotechnology subindustry, AlloVir's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AlloVir's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlloVir's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AlloVir's Debt-to-Equity falls into.

AlloVir Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AlloVir's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.781	+	16.648)	/	145.781
	=	0.19

AlloVir's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.781	+	16.648)	/	145.781
	=	0.19

AlloVir (NAS:ALVR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AlloVir Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AlloVir's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AlloVir (AlloVir) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.allovir.com

AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.

Executives

Vikas Sinha	director, 10 percent owner, officer: See Remarks	C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Edward Miller	officer: General Counsel	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen	officer: Chief Accounting Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams	director	ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B	officer: Chief Commercial Officer	C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy	officer: See Remarks	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal	director, 10 percent owner, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018